Tests subcutaneous tarlatamab in people with small cell lung cancer
Tests subcutaneous tarlatamab for safety in adults with lung cancer.
Plain-language title generated from the registry record
Registry title: Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
Key facts
- Where
- Barcelona, Madrid, Málaga, and Valencia, SpainSee the 4 sites
- Phase
- Phase 1
Where in Spain
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
- Hospital Universitario Regional de MálagaMálaga, SpainTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Amgen
- Trial code
- NCT06598306EU 2024-511838-12-00
- Record updated
- 26 June 2026
- Original description
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.Read full original descriptionShow less
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-Tumor Activity of Subcutaneous Tarlatamab in Subjects With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
The primary objective of this study is to evaluate the safety and tolerability of subcutaneous (SC) tarlatamab.
Inclusion: Participants ≥ 18 years of age (or ≥ legal adult age within country if it is older than 18 years) at time of signing informed consent; Participants with histologically or cytologically confirmed ES-SCLC that progressed or recurred following at least one line of platinum-based anti-cancer therapy for SCLC; Note: Participants with prior treatment for LS-SCLC should have also received another regimen for their recurrent, ES-SCLC disease; Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1; Participants must have adequate organ function (cardiac, pulmonary, kidney, and liver); Participants must be able to have SC injections administered in the abdomen; Participants without measurable disease or tumor tissue (fresh biopsy or archival) available may be permitted after discussion with and approval by Amgen Medical Monitor.
Exclusion: Participants that have received prior DLL3 targeted therapy; Participants with untreated or symptomatic brain metastases or those requiring therapy with steroids; Note: Participants with asymptomatic brain metastatic lesions are allowed following definitive treatment (Amgen Medical Monitor may approve untreated, asymptomatic brain metastasis if local therapy is not required per investigator judgment); Participants with leptomeningeal disease; Participants with baseline oxygen requirement.